NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES NOT STIPULATED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
Today, Wednesday March 22, is the last subscription day for participation in aXichem's rights issue of up to SEK 49.6 million. The subscription price for a new share is SEK 7 and the purpose of the issue is primarily to finance investments in stock, production and marketing of the company's products aXivite and aXiphen, both of which are expected to increase their sales significantly in the coming years.
The notification can be submitted directly to the issuing institution Nordic Issuing (https://nordic-issuing.se/aktuella-uppdrag/axichem-ab-publ/) or via the investor's own bank. However, some banks may have closed the possibility to participate in the offer at an earlier time.
The prospectus, which contains complete terms, conditions and instructions, is available on the Company's, Nordic Issuing AB's and Västra Hamnen Corporate Finance AB's respective websites (www.axichem.com, www.nordic-issuing.se, www.vhcorp.se). The prospectus is also available on the Finansinspektionen's website (www.fi.se).
Financial advisers, legal advisers and issuing agent
Västra Hamnen Corporate Finance AB (publ) acts as financial adviser and Vinge acts as legal adviser to aXichem in connection with the rights issue. Nordic Issuing acts as issuing agent.
